Advanced search
Publication Cover
Future Neurology Volume 1, 2006 - Issue 3
Submit an article Journal homepage
52
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Acamprosate in the treatment of alcoholism: mechanisms and perspectives

Karl F MannCentral Institute of Mental Health, Department of Addictive Behavior & Addiction Medicine, University of Heidelberg, J 5, 68159Mannheim, Germany. [email protected]Correspondence[email protected]
&
Falk KieferCentral Institute of Mental Health, Department of Addictive Behavior & Addiction Medicine, University of Heidelberg, J 5, 68159Mannheim, Germany. [email protected]
Pages 277-284 | Published online: 21 Apr 2006

Bibliography

  • Boismare F , DaoustM, MooreNet al.: A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?Pharmacol. Biochem. Behav.21(5), 787–789 (1984).
  • Le Magnen J , TranG, DurlachJ, Martin C: Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol Alcohol.4(2), 97–102 (1987).
  • Lhuintre JP , DaoustM, MooreNDet al.: Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet1, 1014–1016 (1985).
  • Hillemand B , LhuintreJP, SteruLet al.: Multicenter trial of calcium bis (acetylhomotaurinate) in treatment of alcohol dependence. Rev. de l‘Alcohol34, 9–28 (1989).
  • Mann K : Pharmacotherapy of alcohol dependence: a review of the clinical data.CNS Drugs8, 485–504 (2004).
  • Mann K , LehertP, MorganMY: The efficacy of acamprosate in maintaining abstinence in alcohol-dependent individuals: results of a meta-analysis.Alcohol Clin. Exp. Res.28, 51–63 (2004).
  • Kiefer F , MannK: New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence.Eur. J. Pharmacol.526(1–3), 163–171 (2005).
  • Al Quatari M , BouchenafaO, LittletonJ: Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex.Alcohol Clin. Exp. Res.22, 810–814 (1998).
  • Littleton J , ZieglgansbergerW: Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.Am. J. Addict.12(Suppl. 1), S3–S11 (2003).
  • Rammes G , MahalB, PutzkeJet al.: The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology40, 749–760 (2001).
  • Popp RL , LovingerDM: Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons.Eur. J. Neurosci.394, 221–231 (2000).
  • Harris BR , PrendergastMA, GibsonDAet al.: Acamprosate inhibits the binding and neurotoxic effects of trans- ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin. Exp. Res.26, 1779–1793 (2002).
  • Littleton J : Acamprosate in alcohol dependence: how does it work?Addiction90, 1179–1188 (1995).
  • Berton F , FrancesconiWG, MadambaSG, ZieglgansbergerW, SigginsGR: Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons.Alcohol Clin. Exp. Res.22, 183–191 (1998).
  • Dahchour A , De Witte P: Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog. Neurobiol.60, 343–362 (2000).
  • Wilde MI , WagstaffAJ: Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.Drugs53, 1038–1053 (1997).
  • De Witte P , BachtelerD, SpanagelR: Acamprosate: preclinical data. In:Drugs for Relapse Prevention of Alcoholism. Spanagel R, Mann K (Eds). Birkhäuser Basel, Boston, Berlin, Germany (2005).
  • Kranzler R , TennenH: How to measure relapse in humans. In:Drugs for Relapse Prevention of Alcoholism. Spangel R, Mann K (Eds). Birkhäuser Basel, Boston, Berlin, Germany (2005).
  • Sass H, Soyka M, Mann K, Zieglgansberger W: Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry53, 673–680 (1996).
  • Whitworth AB, Fischer F, Lesch OM et al.: Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet347, 1438–1442 (1996).
  • Rousseaux JP , HersD, FeraugeM: Does acamprosate influence alcohol consumption of weaned alcoholics?J. Pharm. Belg.51, 65–68 (1996).
  • Namkoong K , LeeBO, LeePG, ChoiMJ, LeeE, Korean Acamprosate Clinical Trial Investigators: Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol.38, 135–14 (2003).
  • Chick J , HowlettH, MorganMY, Ritson B: United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol.35, 176–187 (2000).
  • Pelc I , VerbanckP, Le Bon O, Gavrilovic M, Lion K, Lehert P: Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br. J. Psychiatry170, 73–77 (1997).
  • Paille FM , GuelfiJD, PerkinsAC, Royer RJ, Steru L, Parot P: Double-blind, randomized, multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol.30, 239–247 (1995).
  • Garbutt JC , WestS, CareyTS, LohrKN, CrewsFT: Pharmacological treatment of alcohol dependence: a review of the evidence.JAMA281, 1318–1325 (1999).
  • Hopkins JS , GarbuttJC, PooleCL, West SL, Carey TS: Naltrexone and acamprosate: meta-analysis of two medical treatments for alcoholism. Alcohol Clin. Exp. Res.26(Suppl.), 130A (2002).
  • Kranzler HR , Van Kirk J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin. Exp. Res.25, 1335–1341 (2001).
  • Schoechlin C , EngelRR: Meta-analysis of pharmotherapeutic trials. In:Handbook of Alcoholism. Zernig G, Saria A, Kurz M, O‘Malley S (Eds). Innsbruck University Press, Austria, 339–351 (2000).
  • Slattery J , ChickJ, CochraneMet al.: Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3, Glasgow: Health Technology Board of Scotland (2003).
  • Berglund M , ThelanderS, SalaspuroM, FranckJ, AndreassonS, OjehagenA: Treatment of alcohol abuse: an evidence-based review.Alcohol Clin. Ex. Res.27, 1645–1656 (2003).
  • Durbin P , HulotT, ChabacS: Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In:Acamprosate in Relapse Prevention of Alcoholism. Soyka M (Ed.). Springer Verlag, Berlin, Germany (1996).
  • Kiefer F , WiedemannK: Combined therapy: what does acamprosate and naltrexone combination tell us?Alcohol Alcohol.36(6), 542–547 (2004).
  • Mason BJ : Rationale for combining acamprosate and naltrexone for treating alcohol dependence.J. Stud. Alcohol Suppl. (15) 148–156 (2005).
  • Basu D , JhirwalOP, MattooSK: Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India.Am. J. Addict.14, 381–395 (2005).
  • Rubio G , Jimenez-ArrieroMA, PonceG, PalomoT: Naltrexone versus acamprosate: one year follow-up of alcohol dependence of alcohol dependence treatment.Alcohol Alcohol.36, 419–425 (2001).
  • Kiefer F , JahnH, TarnaskeTet al.: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry60, 92–99 (2003).
  • Feeney GF , ConnorJP: Review: acamprosate and naltrexone are safe and effective but have low compliance rates for people with alcohol dependence.Evid. Based Ment. Health8, 14 (2005).
  • The COMBINE Study Research Group: Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: (The COMBINE Study): a pilot feasibility study. Alcohol. Clin. Exp. Res.7, 1107–1122 (2003).
  • Besson J , AebyF, KasasA, LehertP, PotgieterA: Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.Alcohol Clin. Exp. Res.22, 573–579 (1998).
  • Stromberg MF , MacklerSA, VolpicelliJR, O‘BrienCP: Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.Alcohol23, 109–116 (2001).
  • Heyse C J, Moc K, Koob GF: Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology28, 1463–1471 (2003).
  • Kim SG , HanBD, ParkJM, KimMJ, StrombergMF: Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.Psychiatry Clin. Neurosci.58, 30–36 (2004).
  • Mason BJ , GoodmanAM, DixonRMet al.: A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology27, 596–606 (2002).
  • Johnson BA , O‘MalleySS, CirauloDAet al.: Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J. Clin. Psychopharmacol.23, 281–293 (2003).
  • Pelc I , AnsomsC, LehertPet al.: The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction. Alcohol Clin. Exp. Res.26, 1529–1538 (2002).
  • Feeney GF , YoungRM, ConnorJP, Tucker J, McPherson A: Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term outcomes for alcohol dependence improved?Aust. NZ J. Psychiatry36, 622–628 (2002).
  • Mann K , GoodmanA, LehertPet al.: Acamprosate, new data and the search for the acamprosate responder. Alcohol Clin. Exp. Res. In Press (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.